Categories AlphaGraphs, Earnings, Health Care

Earnings: Pfizer edges past Q4 estimates, shares dip on weak outlook

Pfizer (PFE) reported a better-than-expected 2% increase in fourth-quarter revenues to $13.9 billion. Earnings rose to 64 cents per share from 62 cents per share a year ago, surpassing analysts’ estimate of 63 cents per share.

During the quarter, an 8% growth in Innovative Health top-line was partly offset by a 7% decline in its smaller Essential Health segment.

PFE shares were down 3% during pre-market trading on Tuesday as investors were not impressed by the outlook given by the company.

Pfizer said it expects revenues to come in the range of $52 billion to $54 billion for the full year 2019, while adjusted EPS is expected to come in the range of $2.82 to $2.92.

Shares of the pharmaceutical giant have been almost flat in the last 12 months. It closed its last trading session down 2.73% on Monday.

Pfizer Q4 2018 complete earnings call transcript

Albert Bourla, who took charge as the CEO on Jan 1, said, “2019 is expected to be a busy year with important clinical data readouts across our early-, mid- and late-stage pipeline. In the near term, we expect to report pivotal top-line results for tanezumab in chronic lower back pain as well as additional data in osteoarthritis following today’s announcement of a second positive Phase 3 trial.”

Last week, Pfizer was downgraded from Buy to Neutral by UBS analyst Navin Jacob who raised concerns about the company’s patent cliffs for many of its key products. In November, Pfizer lost a patent war in the UK for its drug Lyrica.

Allergan’s stock falls after company reports loss in Q4

The biggest development during the quarter was the joint venture between Pfizer and GlaxoSmithKline plc (GSK) on their consumer health businesses. The transaction is expected to close in the second half of this year and the combined entity will be a giant in the consumer health sector. This will be a key point to watch out for during the results announcement.

 

Get access to timely and accurate verbatim transcripts that are published within hours of the event

Most Popular

General Mills (GIS) Q4 Earnings: Key financials and quarterly highlights

General Mills Inc. (NYSE: GIS) reported fourth quarter 2022 earnings results today. Net sales increased 8% year-over-year to $4.9 billion. Organic net sales rose 13%. Net earnings attributable to General

KB Home (KBH): A look at the homebuilder’s expectations for the year

Shares of KB Home (NYSE: KBH) have dropped 35% year-to-date and 28% over the past 12 months. Last week, the company reported second quarter 2022 earnings results that surpassed expectations

Trade Desk’s stock can strengthen your investment portfolio. Here’s why

Trade Desk, Inc. (NASDAQ: TTD) has remained a much sought-after demand-side platform despite challenging market conditions and growing inflationary pressure, but its stock suffered heavy selling in recent months. The

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top